InflaRx (NASDAQ:IFRX) outlined plans to prioritize development of izicopan, an oral inhibitor of the C5a receptor (C5aR), in ...

Complement represents a chief component of innate immunity in host defense. However, excessive complement activation has been involved in the pathogenesis of inflammatory diseases. In this study, we ...

InflaRx intends to develop izicopan in ANCA-associated vasculitis (AAV), with a secondary goal of establishing rapid proof of concept in ...

Complement C5a is a known mediator of inflammatory and neuropathic pain. In a new study, patients with NMOSD who were in remission and healthy controls were asked to rate their pain on a visual analog ...

JENA, Germany, July 30, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced it ...

InflaRx N.V. (NASDAQ: IFRX) opened Friday in the red. The German-based biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, announced that it will ...

InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that the Company will publish its financial and ...

Please provide your email address to receive an email when new articles are posted on . Targeting the complement pathway using a C5a agonist may be a “game changer” in anti-neutrophil cytoplasmic ...